Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Katie Groves, Francesco Muntoni et al.|The Lancet Neurology|2021Cited by 260
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, A. Nascimento, Wolfgang Müller‐Felber et al.|The Lancet Neurology|2024Cited by 128
P.2.7 6 min walk test 12 month changes in DMD: Correlation with genotypeMarika Pane, Eugenio Mercuri, E. Mazzone et al.|Neuromuscular Disorders|2013Cited by 3